Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

October 06, 2015 9:40 AM ET


Company Overview of Syndax Pharmaceuticals, Inc.

Company Overview

Syndax Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics in oncology. The company’s lead product candidate is entinostat, an epigenetic therapy for treatment-resistant cancers, such as breast cancer and lung cancer, as well as other indications comprising solid tumors and hematological malignancies. Its Entinostat is an oral histone deacetylase inhibitor that targets cancer cell growth and resistance pathways that limit the effectiveness and durability of cancer therapies. The company has a collaborative research and development agreement with the National Cancer Institute; and Genentech. Syndax Pharmaceuticals, In...

400 Totten Pond Road

Suite 110

Waltham, MA 02451

United States

Founded in 2005

13 Employees





Key Executives for Syndax Pharmaceuticals, Inc.

Chief Executive Officer and Director
President and Chief Operating Officer
Age: 44
Co-Founder and Chief Technology Officer
Age: 46
Age: 58
Co-Founder and Advisor
Compensation as of Fiscal Year 2015.

Syndax Pharmaceuticals, Inc. Key Developments

Syndax Pharmaceuticals, Inc. and Merck Announces First Patients Dosed in Phase 1b/2 Clinical Trial of Entinostat and KEYTRUDA

Syndax Pharmaceuticals, Inc. and Merck announced the dosing of the first patients in the Phase 1b/2 clinical trial of Syndax's entinostat in combination with Merck's anti-PD-1 therapy KEYTRUDA in patients with non-small cell lung cancer (NSCLC) or melanoma. The clinical trial, designated ENCORE 601 by Syndax and KEYNOTE 142 by Merck, is evaluating the safety, tolerability and efficacy of entinostat, an oral, small molecule that targets immune regulatory cells, combined with KEYTRUDA, an anti-programmed cell death protein 1 (anti-PD-1) antibody. The ENCORE 601/KEYNOTE 142 trial is designed as a Phase 1b/2 open label clinical trial with dose escalation for entinostat, in which the Phase 1b portion will evaluate the safety and tolerability of the combination of entinostat and KEYTRUDA in patients with NSCLC, and the Phase 2 portion will assess the safety and preliminary efficacy of the combination in separate cohorts in patients with NSCLC or melanoma. The trial will be conducted in the United States and is expected to enroll up to 178 patients.

Syndax Pharmaceuticals, Inc. Appoints Michael Meyers, M.D., Ph.D. as Senior Vice President and Chief Development Officer

Syndax Pharmaceuticals, Inc. announced the hiring of industry veteran Michael Meyers, M.D., Ph.D. to the position of Senior Vice President and Chief Development Officer. Dr. Meyers, who will report to Briggs Morrison, M.D., Chief Executive Officer of Syndax, will become a member of the senior management team, and be responsible for all aspects of clinical development of entinostat, Syndax's oral, small molecule that has direct effects on both cancer cells and immune regulatory cells, potentially enhancing anti-tumor immune responses. Most recently, Dr. Meyers held a number of senior-level roles at Johnson & Johnson (J&J), serving as Vice President, GU Oncology, Compound and Clinical Leader, and as Vice President, Oncology Scientific Innovation in J&J's London Innovation Centre.

Syndax Pharmaceuticals, Inc. Enters Clinical Trial Collaboration with Genentech in Cancer Immunotherapy Combining Entinostat and Atezolizumab

Syndax Pharmaceuticals, Inc. announced that it has entered into a clinical collaboration with Genentech to evaluate the safety, tolerability and preliminary efficacy of Syndax's entinostat, an oral small molecule that targets immune regulatory cells (myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs)), in combination with Genentech's atezolizumab (MPDL3280A), a fully humanized monoclonal antibody targeting protein programmed cell death ligand 1 (PD-L1), in patients with triple-negative breast cancer. Triple-negative breast cancer is estimated to account for 10-20% of all diagnosed breast cancers and is characterized by a lack of expression of estrogen receptor (ER-), progesterone receptor (PR-) and HER2 (HER2-) on the breast cancer cells. Syndax will be responsible for conducting the Phase 1b/2 clinical trial in triple-negative breast cancer and the agreement includes a provision where the parties may extend the collaboration to include a Phase 3 clinical trial as well as additional trials in new indications of mutual interest.

Similar Private Companies By Industry

Company Name Region
Caribou Biosciences, Inc. United States
Mx Biodevices, LLC United States
Trophos Energy, Inc. United States
PSMA Development Company L.L.C. United States
Samumed, LLC United States

Recent Private Companies Transactions

Private Placement
June 1, 2015
Private Placement
January 7, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Syndax Pharmaceuticals, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at